The document describes a phase III clinical trial investigating the efficacy and safety of nintedanib in treating progressive fibrosing interstitial lung disease (PF-ILD), as nintedanib has shown efficacy in treating idiopathic pulmonary fibrosis and may also be effective for other progressive fibrosing ILDs by inhibiting lung fibrosis; the double-blind, randomized, placebo-controlled trial will enroll approximately 600 patients with PF-ILD across various countries and evaluate whether nintedanib can reduce the decline in lung function compared to placebo at 52 weeks.
Bronchial Thermoplasty (BT) Novel Treatment for Patients with Severe AsthmaBassel Ericsoussi, MD
Do our Asthma Patients Know What They Are Missing?Now, A Revolutionary Procedure Can Help Them Lead A Fuller Life.
Bronchial Thermoplasty (BT) Novel Treatment For Patients With Severe Asthma
Bronchial Thermoplasty (BT) Novel Treatment for Patients with Severe AsthmaBassel Ericsoussi, MD
Do our Asthma Patients Know What They Are Missing?Now, A Revolutionary Procedure Can Help Them Lead A Fuller Life.
Bronchial Thermoplasty (BT) Novel Treatment For Patients With Severe Asthma
New technology called Electromagnetic Navigation Bronchoscopy® (ENB) that uses virtual bronchoscopy and real time 3-dimensional CT images that enable me to localize these peripheral lung nodules for diagnosis and treatment. This outpatient procedure is minimally invasive and therefore has a small risk of pneumothorax (2-3%) and its published diagnostic yield rates range from 67% - 86%
Kevin R. Flaherty, MD, MS, prepared progressive fibrosing ILD infographics for this CME activity titled "Progressive Fibrosing Interstitial Lung Disease: Shining a Light on the Latest Clinical Advances." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2LAetT6. CME credit will be available until August 12, 2019.
These lecture notes were prepared by Dr. Hamdi Turkey- Pulmonologist- Department of internal medicine - Taiz university
Do Not Forget To Visit Our Pages On Facebook on the following Links:
https://www.facebook.com/groups/569435236444761/
AND
https://www.facebook.com/groups/690331650977113/
New technology called Electromagnetic Navigation Bronchoscopy® (ENB) that uses virtual bronchoscopy and real time 3-dimensional CT images that enable me to localize these peripheral lung nodules for diagnosis and treatment. This outpatient procedure is minimally invasive and therefore has a small risk of pneumothorax (2-3%) and its published diagnostic yield rates range from 67% - 86%
Kevin R. Flaherty, MD, MS, prepared progressive fibrosing ILD infographics for this CME activity titled "Progressive Fibrosing Interstitial Lung Disease: Shining a Light on the Latest Clinical Advances." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2LAetT6. CME credit will be available until August 12, 2019.
These lecture notes were prepared by Dr. Hamdi Turkey- Pulmonologist- Department of internal medicine - Taiz university
Do Not Forget To Visit Our Pages On Facebook on the following Links:
https://www.facebook.com/groups/569435236444761/
AND
https://www.facebook.com/groups/690331650977113/
Treatment of ILDs by Dr. S.K Jindal | JIndal Chest ClinicJindal Chest Clinic
Interstitial lung disease (ILD) refers to a variety of diseases causing fibrosis in the lungs, leading to stiffness and difficulty in breathing and oxygen delivery to the bloodstream. This presentation gives an overview on "Treatment of ILD". For more information, please contact us: 9779030507.
As a culmination of my time volunteering at Oregon Health and Science University(OHSU), I have crafted a quick informative slideshow that briefs on Idiopathic Pulmonary Fibrosis.
the scenario given at the start of ppt z nt interstitial lung diseases... its a similar diseases to it.... diagnose it urself to differniate it and hv better command over diffferntial diagnosis.
KEY Points of Leicester travel clinic In London doc.docxNX Healthcare
In order to protect visitors' safety and wellbeing, Travel Clinic Leicester offers a wide range of travel-related health treatments, including individualized counseling and vaccines. Our team of medical experts specializes in getting people ready for international travel, with a particular emphasis on vaccines and health consultations to prevent travel-related illnesses. We provide a range of travel-related services, such as health concerns unique to a trip, prevention of malaria, and travel-related medical supplies. Our clinic is dedicated to providing top-notch care, keeping abreast of the most recent recommendations for vaccinations and travel health precautions. The goal of Travel Clinic Leicester is to keep you safe and well-rested no matter what kind of travel you choose—business, pleasure, or adventure.
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
Rate Controlled Drug Delivery Systems, Activation Modulated Drug Delivery Systems, Mechanically activated, pH activated, Enzyme activated, Osmotic activated Drug Delivery Systems, Feedback regulated Drug Delivery Systems systems are discussed here.
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...rightmanforbloodline
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...The Lifesciences Magazine
Cold Sores, medically known as herpes labialis, are caused by the herpes simplex virus (HSV). HSV-1 is primarily responsible for cold sores, although HSV-2 can also contribute in some cases.
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Feeding plate for a newborn with Cleft Palate.pptxSatvikaPrasad
A feeding plate is a prosthetic device used for newborns with a cleft palate to assist in feeding and improve nutrition intake. From a prosthodontic perspective, this plate acts as a barrier between the oral and nasal cavities, facilitating effective sucking and swallowing by providing a more normal anatomical structure. It helps to prevent milk from entering the nasal passage, thereby reducing the risk of aspiration and enhancing the infant's ability to feed efficiently. The feeding plate also aids in the development of the oral muscles and can contribute to better growth and weight gain. Its custom fabrication and proper fitting by a prosthodontist are crucial for ensuring comfort and functionality, as well as for minimizing potential complications. Early intervention with a feeding plate can significantly improve the quality of life for both the infant and the parents.
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareDr. David Greene Arizona
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) - a new supergroup of ILD state?
1. Progressive Fibrosing Interstitial
Lung Disease (PF-ILD)
SC-CRP-00379 /
DE/OFE-181203
Disclaimer:
Nintedanib is an investigational compound in progressive fibrosing interstitial lung diseases other
than IPF and is currently not approved for the treatment of progressive fibrosing interstitial lung
diseases other than IPF!
These slides are intended for education and scientific information only!
2. Interstitial lung disease (ILD)
• ILD encompasses >200 lung disorders
*Not an established clinical diagnosis.
1. ATS/ERS. Am J Respir Crit Care Med 2002;165:277-304.
2. Travis WD et al. Am J Respir Crit Care Med 2013;188:733-48.
Idiopathic Interstitial
Pneumonias (IIPs)1,2
Idiopathic Pulmonary
Fibrosis (IPF)
Idiopathic Non-Specific
Interstitial Pneumonia
(iNSIP)
Respiratory
Bronchiolitis- Interstitial
Lung Disease
Desquamative Interstitial
Pneumonia
Cryptogenic Organising
Pneumonia
Acute Interstitial
Pneumonia
Hypersensitivity
Pneumonitis (HP)
Autoimmune ILDs
Rheumatoid Arthritis
ILD (RA-ILD)
Sjögren’s Syndrome
ILD
Systemic Lupus
Erythematous ILD
Polymyositis and
Dermatomyositis ILD
Mixed Connective
Tissue Disease ILD
Systemic Sclerosis
ILD (SSc-ILD)
Other Connective
Tissue Disease ILDs
Sarcoidosis Other ILDs
ILD
Idiopathic Lymphoid
Interstitial Pneumonia
Idiopathic
Pleuroparenchymal
Fibroelastosis
Unclassifiable IIPs
Interstitial
Pneumonia with
Autoimmune
Features (IPAF)*
• Lymphangioleiomyomatosis (LAM)
• Langerhans Cell Histiocytosis (LCH)
• Drug-Associated ILD
• Other Exposure ILDs
• Vasculitis/Granulomatosis ILDs
• Other Rare ILDs
3. Types of ILD most likely to have a progressive fibrosing
phenotype
Idiopathic Interstitial
Pneumonias (IIPs)1,2
Idiopathic Pulmonary
Fibrosis (IPF)
Idiopathic Non-Specific
Interstitial Pneumonia
(iNSIP)
Respiratory
Bronchiolitis- Interstitial
Lung Disease
Desquamative Interstitial
Pneumonia
Cryptogenic Organising
Pneumonia
Acute Interstitial
Pneumonia
Hypersensitivity
Pneumonitis (HP)
Autoimmune ILDs
Rheumatoid Arthritis
ILD (RA-ILD)
Sjögren’s Syndrome
ILD
Systemic Lupus
Erythematous ILD
Polymyositis and
Dermatomyositis ILD
Mixed Connective
Tissue Disease ILD
Systemic Sclerosis
ILD (SSc-ILD)
Other Connective
Tissue Disease ILDs
Sarcoidosis† Other ILDs
ILD
Idiopathic Lymphoid
Interstitial Pneumonia
Idiopathic
Pleuroparenchymal
Fibroelastosis
Unclassifiable IIPs
Interstitial
Pneumonia with
Autoimmune
Features (IPAF)*
• Lymphangioleiomyomatosis (LAM)
• Langerhans Cell Histiocytosis (LCH)
• Drug-Associated ILD
• Other Exposure ILDs‡
• Vasculitis/Granulomatosis ILDs
• Other Rare ILDs
*Not an established clinical diagnosis. †Stage IV sarcoidosis only. ‡e.g. asbestosis, silicosis.
4. Progressive Fibrosing ILD (PF-ILD)
• Several patients with ILD develop a progressive fibrosing phenotype,
characterised by self-sustaining fibrosis and a deterioration in lung
function, with worsening of symptoms and quality of life
– The proposed terminology for this phenotype is progressive fibrosing ILD
(PF-ILD)
5. Phase III trial of nintedanib in
patients with PF-ILD
1199.247 (ClinicalTrials.gov NCT02999178; EudraCT 2015-003360-37)
Disclaimer:
Nintedanib is an investigational compound in progressive fibrosing interstitial lung diseases other
than IPF and is currently not approved for the treatment of progressive fibrosing interstitial lung
diseases other than IPF!
These slides are intended for education and scientific information only!
Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial
of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res 2017;4:e000212. doi:10.1136/
bmjresp-2017-000212
6. Rationale for investigating nintedanib as a treatment for
PF-ILD
• Working hypothesis: in patients with PF-ILD, the response to lung
injury involves the development of fibrosis that becomes progressive,
self-sustaining and independent of the trigger
• PF-ILD is characterised by worsening respiratory symptoms, declining
lung function, resistance to immunomodulatory therapies and high
mortality
• Nintedanib inhibits fundamental processes in the pathogenesis of lung
fibrosis, irrespective of the trigger,1–4 and has proven efficacy and
safety in the treatment of IPF
• Based on the clinical and mechanistic parallels between IPF and other
types of PF-ILD, nintedanib may be effective in the treatment of PF-
ILD beyond IPF
1. Wollin L et al. J Pharmacol Exp Ther 2014;349:209-20. 2. Wollin L et al. Eur Respir J 2015;45:1434-45.
3. Huang J et al. Ann Rheum Dis 2016;75:883-90. 4. Redente EF et al. Am J Respir Crit Care Med 2016;193:A4170.
7. Design of trial of nintedanib in PF-ILD
R, randomisation.
*Visits to occur every 16 weeks until end of treatment. A follow-up visit will take place 4 weeks after discontinuation of trial medication.
Flaherty KR et.al., BMJ Open Resp Res 2017;4:e000212. doi:10.1136/ bmjresp-2017-000212
8. Key inclusion criteria
• Age ≥18 years
• Physician-diagnosed ILD with features of diffuse fibrosing lung disease of
>10% extent on HRCT, confirmed by central review
• Meeting ≥1 of these criteria for disease progression in the 24 months before
screening, despite treatment with (unapproved) medication used in clinical
practice to treat ILD:
– Relative decline in FVC ≥10% predicted
– Relative decline in FVC ≥5–<10% predicted and worsening respiratory symptoms
– Relative decline in FVC ≥5–<10% predicted and increasing extent of fibrotic
changes on chest imaging
– Worsening of respiratory symptoms and increasing extent of fibrotic changes on
chest imaging
• DLco ≥30 and <80% predicted
• FVC ≥45% predicted
Flaherty KR et.al., BMJ Open Resp Res 2017;4:e000212. doi:10.1136/ bmjresp-2017-000212
9. Primary and main secondary endpoints
Primary endpoint
• Annual rate of decline in FVC (mL/year) at week 52
– There will be two co-primary analysis populations: the first will comprise all
patients, the second will comprise patients with UIP-like fibrotic pattern
only on HRCT
Main secondary endpoints
• Change from baseline in K-BILD total score at week 52
• Time to first acute exacerbation of ILD or death over 52 weeks
• Time to death over 52 weeks
K-BILD, King’s Brief Interstitial Lung Disease Questionnaire.
Flaherty KR et.al., BMJ Open Resp Res 2017;4:e000212. doi:10.1136/ bmjresp-2017-000212
10. Participating countries and timelines
Estimated enrolment: 600
Study start date: January 2017
Estimated study completion date: November 2019
Participating countries: Argentina, Belgium,
Canada, Chile, China, France, Germany, Italy,
Japan, South Korea, Poland, Russia, Spain, UK,
USA
Flaherty KR et.al., BMJ Open Resp Res 2017;4:e000212. doi:10.1136/ bmjresp-2017-000212
11. Dr. Christian Geiß
MSL Respiratory Diseases // Boehringer Ingelheim
christiangeiss@boehringer-ingelheim.com
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Straße 173
55216 Ingelheim am Rhein
Mobil: +49 179 9104244
Telefon: +49 6132 77 83
Fax: +49 6132 72 83